Nirav N. Shah, MD

As the program concludes, Dr. Melody asks Dr. Perales and Dr. Shah to share key takeaways for community oncologists and discuss emerging real-world data and innovations that could improve access to CAR T-cell therapy for patients with large B-cell lymphoma.

Dr. Shah discusses how bridging and holding therapy can be coordinated for patients with symptomatic or rapidly progressing large B-cell lymphoma who face logistical delays before CAR T-cell infusion.

Dr. Melody revisits Mr. R's treatment course after his local oncologist refers him to a regional cell therapy center, highlighting the importance of coordinating treatment for a patient with aggressive, symptomatic large B-cell lymphoma who lives 90 minutes away.

Dr. Shah describes the clinical and functional assessments he uses when evaluating patients with large B-cell lymphoma for CAR T-cell therapy.

Dr. Melody and Dr. Perales discuss how comorbidities should be considered when evaluating patients with large B-cell lymphoma for CAR T-cell therapy.

Dr. Melody introduces a clinical scenario involving Mr. R, a 71-year-old patient with relapsed large B-cell lymphoma, well-controlled hypertension, mild stable chronic kidney disease, preserved independence, and strong caregiver support.

Dr. Perales discusses how clinicians should interpret real-world evidence alongside pivotal clinical trial data in large B-cell lymphoma.

Dr. Shah discusses why real-world evidence (RWE) is particularly important in large B-cell lymphoma, where the three approved CAR T-cell products were evaluated in separate pivotal trials rather than direct head-to-head comparisons.

Dr. Megan Melody introduces the program and welcomes Dr. Miguel Perales and Dr. Nirav Shah before framing the discussion around the evolving role of real-world evidence in large B-cell lymphoma (LBCL).

Nirav N. Shah, MD, MSHP, discusses the design of DAYBreak CLL-201 and its potential importance for chronic lymphocytic leukemia management.

Nirav Shah, MD, discusses the clinical implications and future directions for zamto-cel in patients with relapsed/refractory diffuse large B-cell lymphoma.

Zamtocabtagene autoleucel was associated with a manageable safety profile with no grade 3 or higher CRS and low ICANS rates in relapsed/refractory DLBCL.

Nirav N. Shah, MD, discusses how zamto-cel might address resistance to prior CD19-directed therapy in patients with relapsed/refractory DLBCL.

Nirav Shah, MD, MSHP, discusses evaluating zamtocabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma

Nirav N. Shah, MD, discusses the rationale for launching a phase 2 trial of split-dose R-CHOP in older patients with diffuse large B-cell lymphoma, touching on the unmet needs seen in the treatment of this population.

Nirav N. Shah, MD, discusses primary outcomes from a phase 2 trial investigating split-dose R-CHOP in older patients with diffuse large B-cell lymphoma.

Nirav N. Shah, MD, discusses the background of the phase 1/2 BRUIN trial of pirtobrutinib in patients with heavily pretreated, relapsed/refractory mantle cell lymphoma.

Nirav N. Shah, MD, discusses the long-term efficacy of pirtobrutinib in patients with heavily pretreated, relapsed/refractory mantle cell lymphoma with previous exposure to covalent BTK inhibitors, according to updated data from the phase 1/2 BRUIN trial.

Nirav N. Shah, MD, discusses the investigation of lentiviral bispecific CAR T cells targeting CD20 and CD19 B-cell antigens in patients with relapsed or refractory mantle cell lymphoma.

Nirav N. Shah, MD, discusses findings from a preplanned interim futility analysis of the single-arm phase 2 DALY II USA trial in patients with relapsed/refractory diffuse large B-cell lymphoma.

Nirav N. Shah, MD, discusses the safety of the lentiviral bispecific CAR T cells targeting CD20 and CD19 B-cell antigens, as well as future efforts from a phase 1/2 study of the product in patients with relapsed/refractory mantle cell lymphoma.

Nirav N. Shah, MD, discusses findings from a phase 1/2 study of lentiviral bispecific CAR T cells targeting CD20 and CD19 B-cell antigens in patients with relapsed or refractory mantle cell lymphoma.

Nirav N. Shah, MD, discusses remaining unmet needs with CAR T-cell therapies, and how to ameliorate these challenges for patients with hematologic malignancies.

Nirav N. Shah, MD, discusses treatment options following CAR T-cell therapy failure in hematologic malignancies.

Nirav Shah, MD, MCW, discusses the safety profile of an anti-CD20/anti-CD19 CAR T-cell therapy under investigation in the treatment of patients with non-Hodgkin lymphoma.

Nirav N. Shah, MD, discusses the rationale to evaluate tandem receptor CAR T-cell therapy in non-Hodgkin lymphoma.

Nirav N. Shah, MD, associate professor​, Medical College of Wisconsin, discusses ​the dosing of tandem receptor CAR T-cell therapy in B-cell malignancies.

Nirav N. Shah, MD, assistant professor, Medical College of Wisconsin, discusses the differences between anti–CD19 CAR T-cell therapies.

Nirav N. Shah, MD, assistant professor, Medical College of Wisconsin, discusses ongoing research with CAR T-cell therapy.